Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Daniel Mullins

Showing results (251-260 of 287) with videos related to

Pageof 29
Sort By:
Journal of Clinical Medicine|July 9, 2022
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-AnalysisBenjamin J R Buckley, Deirdre A Lane, Peter Calvert, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Ability of Caprini and Padua Risk-Assessment Models to Predict Venous Thromboembolism in a Nationwide StudyHilary Hayssen, Shalini Sahoo, Phuong Nguyen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2009
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IVC Daniel Mullins, Brian Seal, Enrique Seoane-Vazquez, et al.
Translational Behavioral Medicine|July 13, 2021
Cluster-randomized trial comparing organizationally tailored versus standard approach for integrating an evidence-based cancer control intervention into African American churchesCheryl L Knott, Chang Chen, Janice V Bowie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 24, 2015
Dementia severity and the longitudinal costs of informal care in the Cache County populationGail B Rattinger, Sarah Schwartz, C Daniel Mullins, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 2, 2017
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision MakingMarc L Berger, Harold Sox, Richard J Willke, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2017
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision makingMarc L Berger, Harold Sox, Richard J Willke, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2017
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0Shirley V Wang, Sebastian Schneeweiss, Marc L Berger, et al.
BMC Medicine|January 13, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
BMC Public Health|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Pageof 29

Showing results (251-260 of 287) with videos related to

Sort By:
Pageof 29
Journal of Clinical Medicine|July 9, 2022
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-AnalysisBenjamin J R Buckley, Deirdre A Lane, Peter Calvert, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Ability of Caprini and Padua Risk-Assessment Models to Predict Venous Thromboembolism in a Nationwide StudyHilary Hayssen, Shalini Sahoo, Phuong Nguyen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2009
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IVC Daniel Mullins, Brian Seal, Enrique Seoane-Vazquez, et al.
Translational Behavioral Medicine|July 13, 2021
Cluster-randomized trial comparing organizationally tailored versus standard approach for integrating an evidence-based cancer control intervention into African American churchesCheryl L Knott, Chang Chen, Janice V Bowie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 24, 2015
Dementia severity and the longitudinal costs of informal care in the Cache County populationGail B Rattinger, Sarah Schwartz, C Daniel Mullins, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 2, 2017
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision MakingMarc L Berger, Harold Sox, Richard J Willke, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2017
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision makingMarc L Berger, Harold Sox, Richard J Willke, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2017
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0Shirley V Wang, Sebastian Schneeweiss, Marc L Berger, et al.
BMC Medicine|January 13, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
BMC Public Health|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Pageof 29